About_editors 1..1 - Free

484 Lister et al.68. Shlaes DM, Bouvet A, Devine C, Schlaes JH, Al-Obeid S, Williamson R. Inducible, transferableresistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother1989; 33:198–203.69. Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993; 17:369–379.70. Marchou B, Michea-Hamzehpour M, Lucain C, Pechere JC. Development of beta-lactamresistantEnterobacter cloacae in mice. J Infect Dis 1987; 156:369–373.71. Thomson KS, Sanders CC. Dissociated resistance among fluoroquinolones. AntimicrobAgents Chemother 1994; 38:2095–2100.72. Croisier D, Ettiene M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacinagainst Streptococcus pneumoniae in an experimental model of pneumonia: impact of the lowlevels of fluoroquinolone resistance on the enrichment of resistant mutants. J AntimicrobChemother 2004; 54:640–647.73. Firsov AA, Vostrov SN, Lubenko IY, Drilica K, Portnoy YA, Zinner SH. In vitropharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolonesagainst Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604–1613.74. Drusano G, Johnson D, Rosen M, Standiford M. Pharmacodynamics of a fluoroquinoloneantimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob AgentsChemother 1993; 37:483–490.75. Preston SL, Drusano G, Berman AL, et al. Pharmacodynamics of levofloxacin: a newparadigm for early clinical trials. JAMA 1998; 279:125–129.76. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicinin a pharmacodynamic model to determine importance of antibiotic peak concentration toMIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother1987; 31:1054–1060.77. Marchibanks CR, McKiel JR, Gilbert DH, et al. Dose ranging and fractionation of intravenousciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro pharmacokineticmodel. Antimicrob Agents Chemother 1993; 37:1756–1763.78. Letendre ED, Mantha R, Turgeon PL. Selection of resistance by piperacillin during Pseudomonasaeruginosa endocarditis. J Antimicrob Chemother 1988; 22:557–562.79. Masterton RG, Garner PJ, Harrison NA, et al. Timentin resistance. Lancet 1987; 2:975–976.80. Scully BE, Ores CN, Prince AS, Neu HC. Treatment of lower respiratory tract infections dueto Pseudomonas aeruginosa in patients with cystic fibrosis. Rev Infect Dis 1985; 7(suppl):S669–S674.81. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly–and constitutively-expressed class I beta-lactamases. J Antimicrob Chemother 1990; 25:199–208.82. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1988; 1:109–123.83. Bush K, Freudenberger JS, Sykes RB. Interaction of azthreonam and related monobactamswith beta-lactamase from gram-negative bacteria. Antimicrob Agents Chemother 1982;22:414–420.84. Sakuri Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawaii T. Characteristics ofaztreonam as a substrate inhibitor and inducer for beta-lactamases. J Antibiot 1990;XLIII:403–410.85. Lister PD, Sanders CC, Sanders EC. Cefepime-aztreonam: a unique double beta-lactamcombination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42:1610–1619.86. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drugresistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:645–649.87. Yoneyama H, Nakae T. Mechanism of efficient elimination of protein D2 in outer membraneof imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993;37:2385–2390.88. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities againstPseudomonas aeruginosa: Respective contributions of OprD and efflux systems. AntimicrobAgents Chemother 1999; 43:424–427.89. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities ofMexAB-OprM, MexCD-OprJ and MexXY-OprM efflux pumps in Pseudomonas aeruginosa.Antimicrob Agents Chemother 2000; 44:3322–3327.